A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

I4T-MC-JVDA -

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Trial Summary

Age Range
12 months - 21 years
Conditions the trial is for
Solid Tumors
What the trial is testing?
Ramucirumab
Could I receive a Placebo?
No
Enrollment Goal
29
Trial Dates
Dec 11, 2015 - Jul 16, 2019
How long will I be in the trial?
Your participation could last up to 12 months depending on how you and your tumor respond.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • For part a of the trial, participant must have recurrent or refractory non-central nervous system (CNS) Solid Tumors

  • For part B of the trial, participant must have recurrent or refractory central nervous system (CNS) Tumors

Participants Must Not:

  • Participant must not have other treatment options

  • Participant must not have active or recent history of serious bleeding events

  • Participant must not have active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses

  • Participant must not have active or recent history of dangerously high blood pressure or Headache, convulsions or coma related to high blood pressure

  • Participant must not have an active, non-healing wound or bone fracture

  • Participant must not have a history of organ transplant

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.